Cosmos Health Inc. (COSM) announced that its antiseptic product lines C-Scrub and C-Sept have reached annualized sales exceeding $1.5 million in UK and Greece, with plans to expand distribution across the European Union.
Growth Targets
The company projects EU expansion could drive revenues to $7.4 million and gross profits of $5.3 million, reflecting strong demand for its antiseptic portfolio.
Cosmos also outlined targets to $10.2 million in revenue by 2027, $12.8 million by 2028, and $15.6 million by 2029, supported by continued market penetration and product adoption.
Product Background
C-Scrub is a chlorhexidine-based antiseptic scrub used for surgical hand preparation and skin disinfection, while C-Sept is an antiseptic solution formulated with ethanol and chlorhexidine for preoperative skin cleansing and infection prevention. Both products are marketed as affordable options for hygiene and infection prevention. Their growing adoption in the UK and Greece has positioned Cosmos Health to scale further into new European markets.
Executive Commentary
"We are excited by the strong performance of our antiseptic brands and the opportunity to expand across Europe," said Cosmos Health CEO Greg Siokas. He noted that the company's strategy is focused on leveraging existing distribution networks and building brand recognition in additional EU countries.
COSM has traded between $0.19 and $1.32 over the past year. The stock is currently trading at $0.21, up 6.75%.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.